{"id":43407,"date":"2025-10-15T13:12:00","date_gmt":"2025-10-15T05:12:00","guid":{"rendered":"https:\/\/flcube.com\/?p=43407"},"modified":"2025-10-15T13:12:01","modified_gmt":"2025-10-15T05:12:01","slug":"kailera-therapeutics-secures-600-million-series-b-funding-from-bain-capital-private-equity-to-accelerate-global-obesity-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43407","title":{"rendered":"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline"},"content":{"rendered":"\n<p>Kailera Therapeutics, Inc., the Delaware\u2011registered spin\u2011off of Hengrui Pharma, today announced the closing of a fully funded <strong>$600\u202fmillion Series\u202fB financing round<\/strong> led by <strong>Bain Capital Private Equity<\/strong>. The capital injection will underpin the company\u2019s global Phase\u202fIII program for its lead obesity candidate <strong>KAI\u20119531<\/strong>, an injectable dual GLP\u20111\/GIP receptor agonist, and will propel the next\u2011generation oral GLP\u20111 agonist <strong>KAI\u20117535<\/strong> into worldwide clinical development.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-funding-snapshot\">Funding Snapshot<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Investor<\/strong><\/td><td>Bain Capital Private Equity (lead)<\/td><\/tr><tr><td><strong>Capital Raised<\/strong><\/td><td>$600\u202fmillion (Series\u202fB)<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>1) Phase\u202fIII global trial of KAI\u20119531 (injectable) 2) Phase\u202fIII global rollout of KAI\u20117535 (oral) 3) Early\u2011stage programs (KAI\u20114729, oral KAI\u20119531) 4) Strategic asset development &amp; licensing rights<\/td><\/tr><tr><td><strong>Equity Stake<\/strong><\/td><td>Bain Capital will hold a minority equity position; Hengrui retains 19.9\u202f% ownership<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pipeline-highlights\">Pipeline Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Candidate<\/th><th>Status<\/th><th>Clinical Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>KAI\u20119531<\/strong><\/td><td>Lead obesity drug<\/td><td>Global Phase\u202fIII trial (injectable dual GLP\u20111\/GIP agonist) \u2013 \u201cbest\u2011in\u2011category\u201d weight\u2011loss profile<\/td><\/tr><tr><td><strong>KAI\u20117535<\/strong><\/td><td>Oral GLP\u20111 agonist<\/td><td>Transitioning to global Phase\u202fIII after Phase\u202fII success in China<\/td><\/tr><tr><td><strong>KAI\u20114729<\/strong><\/td><td>Tri\u2011agonist (GLP\u20111\/GIP\/Glucagon)<\/td><td>Early\u2011stage development<\/td><\/tr><tr><td><strong>Oral KAI\u20119531<\/strong><\/td><td>Once\u2011daily tablet<\/td><td>Formulation and clinical testing underway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Kailera also holds rights to new formulations of licensed products and first\u2011refusal options on selected assets from Hengrui Pharma\u2019s broader metabolic\u2011disease portfolio.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Leverage<\/strong> \u2013 The $600\u202fmillion infusion positions Kailera to complete its global obesity program ahead of competitors in the rapidly expanding GLP\u20111 market.<\/li>\n\n\n\n<li><strong>Investor Confidence<\/strong> \u2013 Bain Capital\u2019s partnership signals strong validation of Kailera\u2019s science and growth trajectory.<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong> \u2013 Rights to additional Hengrui assets provide a diversified pipeline and potential revenue streams beyond obesity.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-kailera-therapeutics\">About Kailera Therapeutics<\/h3>\n\n\n\n<p>Founded in May\u202f2024 and incorporated in Delaware, Kailera Therapeutics is the exclusive global developer and commercializer of four Hengrui\u2011licensed metabolic disease assets outside Greater China. Hengrui Pharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">\\<\/a>) maintains a 19.9\u202f% equity stake.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements regarding future performance, product development, and regulatory approvals. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kailera Therapeutics, Inc., the Delaware\u2011registered spin\u2011off of Hengrui Pharma, today announced the closing of a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,2586,4228,956,852],"class_list":["post-43407","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-diabetes","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-kailera-therapeutics","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kailera Therapeutics, Inc., the Delaware\u2011registered spin\u2011off of Hengrui Pharma, today announced the closing of a fully funded $600\u202fmillion Series\u202fB financing round led by Bain Capital Private Equity. The capital injection will underpin the company\u2019s global Phase\u202fIII program for its lead obesity candidate KAI\u20119531, an injectable dual GLP\u20111\/GIP receptor agonist, and will propel the next\u2011generation oral GLP\u20111 agonist KAI\u20117535 into worldwide clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43407\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline\" \/>\n<meta property=\"og:description\" content=\"Kailera Therapeutics, Inc., the Delaware\u2011registered spin\u2011off of Hengrui Pharma, today announced the closing of a fully funded $600\u202fmillion Series\u202fB financing round led by Bain Capital Private Equity. The capital injection will underpin the company\u2019s global Phase\u202fIII program for its lead obesity candidate KAI\u20119531, an injectable dual GLP\u20111\/GIP receptor agonist, and will propel the next\u2011generation oral GLP\u20111 agonist KAI\u20117535 into worldwide clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43407\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T05:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T05:12:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1506.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline\",\"datePublished\":\"2025-10-15T05:12:00+00:00\",\"dateModified\":\"2025-10-15T05:12:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407\"},\"wordCount\":361,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1506.webp\",\"keywords\":[\"Diabetes\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Kailera Therapeutics\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43407#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43407\",\"name\":\"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1506.webp\",\"datePublished\":\"2025-10-15T05:12:00+00:00\",\"dateModified\":\"2025-10-15T05:12:01+00:00\",\"description\":\"Kailera Therapeutics, Inc., the Delaware\u2011registered spin\u2011off of Hengrui Pharma, today announced the closing of a fully funded $600\u202fmillion Series\u202fB financing round led by Bain Capital Private Equity. The capital injection will underpin the company\u2019s global Phase\u202fIII program for its lead obesity candidate KAI\u20119531, an injectable dual GLP\u20111\\\/GIP receptor agonist, and will propel the next\u2011generation oral GLP\u20111 agonist KAI\u20117535 into worldwide clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43407\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1506.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1506.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43407#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Kailera Therapeutics, Inc., the Delaware\u2011registered spin\u2011off of Hengrui Pharma, today announced the closing of a fully funded $600\u202fmillion Series\u202fB financing round led by Bain Capital Private Equity. The capital injection will underpin the company\u2019s global Phase\u202fIII program for its lead obesity candidate KAI\u20119531, an injectable dual GLP\u20111\/GIP receptor agonist, and will propel the next\u2011generation oral GLP\u20111 agonist KAI\u20117535 into worldwide clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43407","og_locale":"en_US","og_type":"article","og_title":"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline","og_description":"Kailera Therapeutics, Inc., the Delaware\u2011registered spin\u2011off of Hengrui Pharma, today announced the closing of a fully funded $600\u202fmillion Series\u202fB financing round led by Bain Capital Private Equity. The capital injection will underpin the company\u2019s global Phase\u202fIII program for its lead obesity candidate KAI\u20119531, an injectable dual GLP\u20111\/GIP receptor agonist, and will propel the next\u2011generation oral GLP\u20111 agonist KAI\u20117535 into worldwide clinical development.","og_url":"https:\/\/flcube.com\/?p=43407","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T05:12:00+00:00","article_modified_time":"2025-10-15T05:12:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1506.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43407#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43407"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline","datePublished":"2025-10-15T05:12:00+00:00","dateModified":"2025-10-15T05:12:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43407"},"wordCount":361,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43407#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1506.webp","keywords":["Diabetes","Hengrui Pharmaceuticals","HKG: 1276","Kailera Therapeutics","SHA: 600276"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43407#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43407","url":"https:\/\/flcube.com\/?p=43407","name":"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43407#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43407#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1506.webp","datePublished":"2025-10-15T05:12:00+00:00","dateModified":"2025-10-15T05:12:01+00:00","description":"Kailera Therapeutics, Inc., the Delaware\u2011registered spin\u2011off of Hengrui Pharma, today announced the closing of a fully funded $600\u202fmillion Series\u202fB financing round led by Bain Capital Private Equity. The capital injection will underpin the company\u2019s global Phase\u202fIII program for its lead obesity candidate KAI\u20119531, an injectable dual GLP\u20111\/GIP receptor agonist, and will propel the next\u2011generation oral GLP\u20111 agonist KAI\u20117535 into worldwide clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43407#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43407"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43407#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1506.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1506.webp","width":1080,"height":608,"caption":"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43407#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kailera Therapeutics Secures $600\u202fMillion Series\u202fB Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1506.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43407"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43407\/revisions"}],"predecessor-version":[{"id":43409,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43407\/revisions\/43409"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43408"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}